These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 9738462)

  • 1. p53 and the ribosomal protein L5 participate in high molecular mass complex formation with protein kinase CK2 in murine teratocarcinoma cell line F9 after serum stimulation and cisplatin treatment.
    Guerra B; Issinger OG
    FEBS Lett; 1998 Aug; 434(1-2):115-20. PubMed ID: 9738462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of protein kinase CK2 protein subunits and p53 in F9 teratocarcinoma cells in the absence and presence of cisplatin.
    Küpper M; Köster M; Schmidt-Spaniol I; Wagner-Gillen I; Issinger OG
    Cell Mol Biol Res; 1994; 40(5-6):587-92. PubMed ID: 7735333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determination of mRNA, and protein levels of p53, MDM2 and protein kinase CK2 subunits in F9 cells after treatment with the apoptosis-inducing drugs cisplatin and carboplatin.
    Siemer S; Ornskov D; Guerra B; Boldyreff B; Issinger OG
    Int J Biochem Cell Biol; 1999 Jun; 31(6):661-70. PubMed ID: 10404639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The carboxy terminus of p53 mimics the polylysine effect of protein kinase CK2-catalyzed MDM2 phosphorylation.
    Guerra B; Götz C; Wagner P; Montenarh M; Issinger OG
    Oncogene; 1997 Jun; 14(22):2683-8. PubMed ID: 9178766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phosphorylation of murine double minute clone 2 (MDM2) protein at serine-267 by protein kinase CK2 in vitro and in cultured cells.
    Hjerrild M; Milne D; Dumaz N; Hay T; Issinger OG; Meek D
    Biochem J; 2001 Apr; 355(Pt 2):347-56. PubMed ID: 11284721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p53-Dependent and -independent responses to cisplatin in mouse testicular teratocarcinoma cells.
    Zamble DB; Jacks T; Lippard SJ
    Proc Natl Acad Sci U S A; 1998 May; 95(11):6163-8. PubMed ID: 9600935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protein kinase CK2-dependent regulation of p53 function: evidence that the phosphorylation status of the serine 386 (CK2) site of p53 is constitutive and stable.
    McKendrick L; Milne D; Meek D
    Mol Cell Biochem; 1999 Jan; 191(1-2):187-99. PubMed ID: 10094408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of p53 mediated transactivation by the beta-subunit of protein kinase CK2.
    Schuster N; Prowald A; Schneider E; Scheidtmann KH; Montenarh M
    FEBS Lett; 1999 Mar; 447(2-3):160-6. PubMed ID: 10214938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel system to investigate the phosphorylation of the p53 tumor suppressor protein by the protein kinase CK2.
    McKendrick L; Meek DW
    Cell Mol Biol Res; 1994; 40(5-6):555-61. PubMed ID: 7735330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of the DNA binding of p53 by its interaction with protein kinase CK2.
    Prowald A; Schuster N; Montenarh M
    FEBS Lett; 1997 May; 408(1):99-104. PubMed ID: 9180277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mapping of the interaction sites of the growth suppressor protein p53 with the regulatory beta-subunit of protein kinase CK2.
    Appel K; Wagner P; Boldyreff B; Issinger OG; Montenarh M
    Oncogene; 1995 Nov; 11(10):1971-8. PubMed ID: 7478515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of instability of p34(cdc2) expression by treatment with cisplatin (CDDP) in mouse teratocarcinoma F9 cells.
    Doi T; Morita T; Wakabayashi N; Sumi T; Iwai SA; Amekawa S; Sakuda M; Nishimune Y
    Cancer Lett; 2002 Feb; 176(1):75-80. PubMed ID: 11790456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of the DNA-binding ability of latent p53 protein by protein kinase C is abolished by protein kinase CK2.
    Pospísilová S; Brázda V; Kucharíková K; Luciani MG; Hupp TR; Skládal P; Palecek E; Vojtesek B
    Biochem J; 2004 Mar; 378(Pt 3):939-47. PubMed ID: 14640983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p53 serine 392 phosphorylation increases after UV through induction of the assembly of the CK2.hSPT16.SSRP1 complex.
    Keller DM; Lu H
    J Biol Chem; 2002 Dec; 277(51):50206-13. PubMed ID: 12393879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protein kinase CK2 interacts with a multi-protein binding domain of p53.
    Götz C; Scholtes P; Prowald A; Schuster N; Nastainczyk W; Montenarh M
    Mol Cell Biochem; 1999 Jan; 191(1-2):111-20. PubMed ID: 10094399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Wild-type p53 inhibits protein kinase CK2 activity.
    Schuster N; Götz C; Faust M; Schneider E; Prowald A; Jungbluth A; Montenarh M
    J Cell Biochem; 2001; 81(1):172-83. PubMed ID: 11180407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FAS-associated factor 1 interacts with protein kinase CK2 in vivo upon apoptosis induction.
    Guerra B; Boldyreff B; Issinger OG
    Int J Oncol; 2001 Dec; 19(6):1117-26. PubMed ID: 11713579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA damage triggers DRB-resistant phosphorylation of human p53 at the CK2 site.
    Blaydes JP; Hupp TR
    Oncogene; 1998 Aug; 17(8):1045-52. PubMed ID: 9747884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sensitization of tumor cells to Apo2 ligand/TRAIL-induced apoptosis by inhibition of casein kinase II.
    Ravi R; Bedi A
    Cancer Res; 2002 Aug; 62(15):4180-5. PubMed ID: 12154014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of a CK2 phosphorylation site in mdm2.
    Götz C; Kartarius S; Scholtes P; Nastainczyk W; Montenarh M
    Eur J Biochem; 1999 Dec; 266(2):493-501. PubMed ID: 10561590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.